{"id":"W2762653748","doi":"10.1200/jco.2017.35.15_suppl.9074","title":"Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>BRAF</i><sup>V600</sup> mutation.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Vemurafenib; Internal medicine; Oncology; Cohort; Clinical endpoint; Rash; Lung cancer; Adverse effect; Expanded access; Progression-free survival; non-small cell lung cancer (NSCLC); Nausea; Cancer; Clinical trial; Metastatic melanoma; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006447681,0.0003519744,0.0008650313,0.0002077816,0.0001303033,0.0004575366,0.0002233574,0.0003371139,0.001589814],"category_scores_gemma":[0.0008442883,0.0001978687,0.0006050354,0.0002063148,0.0001853802,0.0004471941,0.0002501665,0.0008283849,0.0003126111],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004168796,"about_ca_system_score_gemma":0.0004099169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003020709,"about_ca_topic_score_gemma":0.001131693,"domain_scores_codex":[0.999793,0.0001003801,0.00001733526,0.00003419943,0.00002453703,0.00003056783],"domain_scores_gemma":[0.999673,0.00008251302,0.0000885944,0.00001344371,0.00002160996,0.0001209511],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5127351,0.02180987,0.09640481,0.001964612,0.002132628,0.001114847,0.000536264,0.003439974,0.03649091,0.0001846907,0.006804701,0.3163816],"study_design_scores_gemma":[0.1906359,0.4681164,0.3121349,0.0001781993,0.001922112,0.002459188,0.0002806438,0.004496576,0.006646957,0.0003957376,0.01265876,0.0000746482],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967684,0.001613237,0.0001005904,0.0001187006,0.00001955384,0.0002224921,0.0004087914,0.00001783575,0.0007304474],"genre_scores_gemma":[0.9976454,0.0006133286,0.000211847,0.0001622391,0.00003574912,0.0001666329,0.0007535679,0.000004110131,0.0004070084],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001589814,"threshold_uncertainty_score":0.005318403,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02980960432127084,"score_gpt":0.3542964915474961,"score_spread":0.3244868872262253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}